Skip to main content
TipRanks
Go Ultimate75% OFF

Philogen SpA (PHIL) AI Stock Analysis

10 Followers
IT:PHIL

Philogen SpA

(Milan:PHIL)

Select Model
Rating:77Outperform
Price Target:EUR 25.00▲(18.76% Upside)
Action:reiterated
Date:10/03/26

The score is supported primarily by strong recent financial performance (high margins, strong cash conversion, low leverage) and very attractive valuation (low P/E and solid yield). These positives are tempered by weak technical signals (below key moving averages with negative MACD and sub-50 RSI) and the company’s historically volatile growth and cash-flow momentum.

Positive Factors
Conservative leverageVery low debt relative to equity gives Philogen meaningful financial flexibility while it advances clinical programs and seeks partnering opportunities. A conservative balance sheet can reduce financing pressure and preserve capacity to fund development or absorb operating volatility over the coming quarters.
Negative Factors
Unstable profitability historyThe sharp shift from negative historical returns and losses to very high recent profitability shows that earnings quality has not yet been consistent across cycles. This history makes it harder to treat current margins as durable and raises the risk that future results could vary materially.

Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)

-20%-10%0%10%20%30%IT:PHIL-6.35%EWI+14.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 615.56M
Dividend Yield
3.33%
Average Volume (3M)
16.98K
Price to Earnings (P/E)
3.8
Beta (1Y)
-0.11
Revenue Growth
294.92%
EPS Growth
390.98%
Country
Italy
Employees
230
Sector
General
Sector Strength
55
Industry
Biotechnology

Philogen SpA Business Overview & Revenue Model

Company Description

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma ski...

How the Company Makes Money

Philogen’s ability to generate revenue is primarily tied to advancing its proprietary drug candidates and monetizing its antibody-targeting technology through partnering. Key potential revenue streams include: (1) Licensing and collaboration income:...

Philogen SpA Financial Statement Overview

Summary

Strong inflection to very high profitability and cash generation in 2024–TTM with excellent cash conversion and low leverage. The main offset is volatility: revenue growth and free-cash-flow momentum have swung sharply and prior years were loss-making, reducing confidence in durability.

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue315.27M314.32M74.00M23.13M23.71M2.50M
Gross Profit274.87M271.84M54.42M5.67M10.53M-8.14M
EBITDA256.58M255.84M44.75M-2.05M-1.17M-12.98M
Net Income224.98M229.68M45.29M-6.16M-5.38M-15.72M
Balance Sheet
Total Assets395.51M437.33M168.45M119.27M125.83M132.75M
Cash, Cash Equivalents and Short-Term Investments337.14M379.22M113.73M75.34M86.20M101.68M
Total Debt11.44M10.88M11.54M14.91M15.76M16.49M
Total Liabilities63.82M63.46M29.80M28.68M27.91M27.67M
Stockholders Equity331.69M373.86M138.66M90.59M97.92M105.09M
Cash Flow
Free Cash Flow262.41M268.05M38.67M-10.37M-9.15M-25.85M
Operating Cash Flow264.45M271.44M40.84M-4.82M-4.94M-19.03M
Investing Cash Flow-239.72M-171.82M-22.28M159.00K24.20M-47.77M
Financing Cash Flow-30.77M-2.99M-3.78M-4.17M-3.78M63.05M

Philogen SpA Technical Analysis

Technical Analysis SentimentNegative
Last Price21.05

Price Trends

50DMA21.96Negative
100DMA22.92Negative
200DMA22.20Negative

Market Momentum

MACD-0.24Negative
RSI46.39Neutral
STOCH69.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 21.05 is above the 20-day moving average (MA) of 21.05, below the 50-day MA of 21.96, and below the 200-day MA of 22.20, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 69.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IT:PHIL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IT:DIAIT:DIA79OutperformEUR 4.55B26.2713.91%1.54%-3.13%-22.16%
IT:PHILIT:PHIL77OutperformEUR 615.56M3.7963.77%3.33%294.92%390.98%
IT:RECIT:REC71OutperformEUR 10.87B20.6524.82%2.55%8.27%30.25%
IT:ELNIT:ELN67NeutralEUR 1.34B14.5217.54%1.50%2.55%22.08%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IT:FDAIT:FDA43NeutralEUR 20.24M-1.04-54.95%―13.94%―

* General Sector Average

Performance Comparison

-50%0%50%IT:PHILIT:DIAIT:ELNIT:FDAIT:RECIT:ARBSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IT:PHIL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IT:PHILPhilogen SpA21.05-1.43-6.35%
IT:DIADiaSorin S.p.A.84.3226.5545.95%
IT:ELNEl.En. S.p.A.16.705.6050.42%
IT:FDAFidia Spa0.02-0.18-91.96%
IT:RECRecordati Industria Chimica e Farmaceutica SPA52.651.763.46%
IT:ARBSArterra Bioscience SpA3.010.103.44%

Philogen SpA Corporate Events

Philogen Updates on Modest Progress in Ongoing Share Buyback Program

Sep 28, 2026

Philogen has provided an update on its ongoing share buyback program, reporting the repurchase of 3,766 treasury shares on Euronext Milan between 21 and 25 September 2026 for a total consideration of €84,420.13. These latest transactions raise the to...

Philogen expands treasury stake with continued share buybacks

Sep 14, 2026

Philogen S.p.A., a biotech group active in oncology and other severe diseases, leverages proprietary antibody and DNA-encoded library technologies to design tumor-targeting therapeutics, aiming to address conditions where current treatments remain in...

Philogen Adds to Treasury Stock with Latest Share Buyback Tranche

Sep 7, 2026

Philogen has reported fresh activity under its share buyback program, disclosing the repurchase of 3,626 shares on Euronext Milan between 31 August and 2 September 2026 at an average price of €22.9647, for a total outlay of €83,269.99. These latest p...

Philogen Reports Mediobanca Share Purchase on Italian Market

Sep 2, 2026

Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a Milan-based financial institution acting in an engagement capacity. The communication relates to Philogen’s ordinary shares, underscoring the company’s compli...

Mediobanca Reports Purchase of Philogen Shares on Italian Market

Aug 3, 2026

Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a major Italian financial institution acting under an unspecified engagement. The transaction, executed on July 22, 2026, on the EXM market segment, involved th...

Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital

Jul 27, 2026

Philogen S.p.A. has provided an update on its share buyback program, reporting the purchase of 230 treasury shares on Euronext Milan between 20 and 24 July 2026 at an average price of €22.80 per share, for a total outlay of €5,244.00. These latest tr...

Philogen resubmits strengthened EMA application for melanoma drug Nidlegy

Jul 27, 2026

Philogen has resubmitted an updated marketing authorization application to the European Medicines Agency for Nidlegy as a neoadjuvant therapy in adult patients with locally advanced, fully resectable melanoma. The dossier is now supported by longer m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 03, 2026